Lung Cancer Therapeutics

Published by: Global Industry Analysts

Published: Jul. 1, 2009 - 842 Pages

Table of Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Chemotherapy Drugs

Targeted Drugs

II. EXECUTIVE SUMMARY

1.MARKET OVERVIEW

Lung Cancer Therapeutics - Driven by Next Generation Drugs

New Therapies Drive NSCLC Market

Market Value of Taxanes to Decrease by 2015

Lung Cancer - The Killer Disease

Lung Cancer - A Quick Glance at Global Statistics

Asia Heading for Possible Lung Cancer Epidemic

Table 1: Global Incidence of Lung Cancer (2008): Percentage Share Breakdown by Region (includes corresponding Graph/Chart)

2.LUNG CANCER - AN INSIGHT

Lungs - Critical for Oxygen Supply

Lung Cancer - An Introduction

Common Symptoms of Lung Cancer

Types of Lung Cancer

Non-Small Cell Lung Cancer

NSCLC - At a Glance

Small Cell Lung Cancer

Risk Factors for Lung Cancer

Female Smokers at Higher Risk of DevelopingLung Cancer

Lung Cancer Diagnostics

Lung Cancer Staging

Staging for Non-Small Cell Lung Cancer

Staging for Small Cell Lung Cancer

3.LUNG CANCER TREATMENT MODALITIES

Surgery

Radiation Therapy

Chemotherapy

Combination Therapy

Photodynamic Therapy

Vaccines

Common Treatment Modalities for SCLC and NSCLCLung Cancers

Pain Management

4.INTRODUCTION TO LUNG CANCERTHERAPEUTICS

Chemotherapy

Drug Administration

Overview of Chemotherapy Regimens and Drugs

Side Effects of Chemotherapy

Targeted Therapy

Chemotherapy Drugs for SCLC Treatment

Chemotherapy Drugs for NSCLC Treatment

Major Chemotherapy Drugs

Select Chemotherapy Drugs Used in the Treatment ofLung Cancer by Brand and Generic Name

Overview of Select Chemotherapeutic Drugs

Alimta

Carboplatin and Cisplatin

Docetaxel

Paclitaxel

Xyotax

Gemcitabine

Gefitinib

Irinotecan

Vinorelbine (Navelbine®)

5.PRODUCT DEVELOPMENT IN NSCLCTHERAPEUTICS

R&D Focus in NSCLC Treatment

Drug Development Process - Growth Opportunities &Challenges

Product Pipeline for NSCLC Treatment

Product Pipeline for NSCLC Treatment

Select (Ongoing/Completed) Clinical Trials forNSCLC Treatment

Companies Focus on Molecular Targeted Therapies

Molecular Targeted Therapies - Overview of SelectProduct Candidates

Aflibercept (VEGF-Trap) - Sanofi Aventis/Regeneron

BIBW 2992 - Boehringer Ingelheim

Erbitux (cetuximab) - ImClone/Merck Serono/Bristol-Myers Squibb

Nexavar (sorafenib) - Bayer Schering

Recentin (cediranib) - AstraZeneca

Sutent (sunitinib) - Pfizer

Zactima (vandetanib) - AstraZeneca

Zolinza (vorinostat) - Merck & Co

Pipeline for Cytotoxic Therapy - Overview of SelectProducts

Abraxane (albumin-bound paclitaxel) - Abraxis

Glutoxim (NOV-002) - Novelos

Javlor (vinflunine) - Pierre Fabre

Lipoplatin (liposomal cisplatin) - Regulon

Xyotax (paclitaxel polyglumex) - Cell Therapeutics/Novartis

6.PRODUCT APPROVALS/INNOVATIONS/LAUNCHES

Intas Biopharmaceuticals to Introduce Gefitinib in India

Celgene Receives FDA Fast Track Product Designationfor Amrubicin

EMEA Approves ALIMTA for First-Line Therapy ofAdvanced NSCLC

Celgene’s Cancer Drug Receives Orphan Drug Statusfrom European Commission

Alimta Receives FDA Approval

Roche Receives Approval from European Authoritiesfor Avastin

OSI Pharmaceuticals Introduces Tarceva in Japan

Shanghai Medipharm Introduces TNT Antibody forTreating Lung Cancer

Natco Pharma Unveils an Injectible Drug forLung Cancer, Pemnat

Roche Scientific Introduces Tarceva in the Indian Market

GlaxoSmithKline’s HYCAMTIN® Receives MarketingApproval from EC

Genzyme Launches New Genetic Mutation Test to AidLung Cancer Treatment

UT Southwestern Medical Center Researchers DiscoverNew Anti-Cancer Drug

Agennix's Talactoferrin Alfa Program Obtains Fast TrackDesignation from FDA

Novelos Therapeutics’ NOV-002 Receives Fast TrackDesignation from FDA

7.RESEARCH & CLINICAL TRIALS

Novartis Commences Phase III Clinical Trial of ASA404

Results of BR.21 Trials

Genentech Announces Results of Phase III BETALung Trial

Results of SATURN Clinical Trial

Results of Zactima’s Clinical Trials

Results of Erbitux’s Phase III Trials

Results of Roche’s AVAiL Clinical Trial

GlaxoSmithKline Conducts Phase III Clinical Trial ofLung Cancer Vaccine

FASgen Announces Research Results of FAS093

The Cuban Regulatory Agency Registers a NewTherapeutic Lung Cancer Vaccine

Gemin X Commences Clinical Trials of GX15-070

Antisoma and Biomira Announce Clinical Trial Resultsof Lung Cancer Drugs

OSI Pharmaceuticals Commences Phase III Clinical Trialsof Tarceva®

Northwest Gets FDA Clearance to Conduct Clinical Trialsfor Lung Cancer Vaccine

University of Kentucky Conducts Clinical Trials onLung Cancer Vaccine

Poniard Enrolls in Phase II Small Cell Lung CancerClinical Trials of Picoplatin

Sunesis Pharmaceuticals Starts Phase II Clinical Trialsof SNS-595

Ligand Pharmaceuticals Tables Clinical Results ofTargretin®

Bayer and Onyx Start Phase III Trial of Nexavar®

Abraxis Announces Clinical Results of ABRAXANE®

Introgen Conducts Phase II Clinical Trials of INGN 225

YM BioSciences Commences Clinical Trial of Nimotuzumab

8.RECENT INDUSTRY ACTIVITY

Merck Agrees to Merge with Shering-Plough

Abbott Molecular Signs Agreement with Genentech, OSIand Roche

IMUC Acquires Monoclonal Antibody Technologyfrom MDC

Quest PharmaTech Enters into Collaboration with BCCancer Agency

Daiichi Sankyo Acquires U3 Pharma

MacroGenics Takes Over Raven Biotechnologies

Roche Acquires Piramed

Bristol-Myers Squibb Acquires Kosan Biosciences

Point Therapeutics and DARA Biosciences Ink MergerAgreement

Celgene Acquires Pharmion

Pfizer to Takeover Serenex

ATS Acquires Majority Stake in GANYMEDPharmaceuticals

NCCN, AstraZeneca and Abraxis Enter into Collaboration

Eli Lilly Agrees to Take Over ImClone Systems

CytRx Takes Over Innovive Pharmaceuticals

Abbott Extends Discovery Partnership with Caprion

Bristol-Myers and ImClone to Expand the ClinicalDevelopment Program for ERBITUX

Biomoda and New Mexico Tech Enter intoa Collaborative Agreement

Binex Inks Sponsored Research Agreement with MaxCyte

Simcere Pharmaceutical Acquires Master Luck

Dako Enters into Collaboration with OSI, Roche, andGenentech

Biomira and Merck Sign Revised Supply andCollaboration Agreements

ImClone Systems Terminates Development Agreementwith UCB

Astellas Pharma’s US Subsidiary Acquires Agensys

Antisoma Enters into an Agreement with Novartis

Pharmacyclics Files NDA for Xcytrin® Injection

9.FOCUS ON SELECT GLOBAL PLAYERS

AstraZeneca PLC (UK)

Bristol-Myers Squibb Co. (US)

Eli Lilly & Co. (US)

F. Hoffmann-La Roche Ltd (Switzerland)

Genentech, Inc. (US)

GlaxoSmithKline Plc (UK)

Novartis Pharmaceuticals Corporation (US)

OSI Pharmaceuticals, Inc. (US)

Sanofi-Aventis (France)

Companies with Pipeline Drugs

AbGenomics International Inc. (US)

ImClone Systems, Inc. (US)

Pfizer, Inc. (US)

Merck Serono International S.A. (Switzerland)

Merck & Co. Ltd. (US)

Telik, Inc. (US)

Woomera Therapeutics, Inc. (US)

10.GLOBAL MARKET PERSPECTIVE

Table 2: World Recent Past, Current & Future Analysis forNon-Small Cell Lung Cancer Therapeutics Market byGeographic Region - US, Europe and Rest of World Independently Analyzed with Annual Revenues inUS$ Million for Years 2005 through 2015 (includescorresponding Graph/Chart)

Table 3: World 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Europe and Restof World Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis

NSCLC Drug Market to Rise Sharply

Lung Cancer Prevalence

A Major Cause of Death among US Women

Statistics

Market Scenario

FDA Places New Restrictions on Iressa

Innovative Technology Enables Early Diagnosisof Lung Cancer

Avastin to Emerge as the Preferred NSCLCDrug in the US

Product Approvals/Clinical Trials/Introductions/Launches

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 4: US Recent Past, Current & Future Analysis forNon-Small Cell Lung Cancer Therapeutics by Segment - Chemotherapy Drugs and Targeted Drugs Markets Independently Analyzed with Annual Revenues inUS$ Million for Years 2005 through 2015(includes corresponding Graph/Chart)

Table 5: US 10-Year Perspective for Non-Small CellLung Cancer Therapeutics by Segment - Percentage Breakdown of Annual Revenues for ChemotherapyDrugs and Targeted Drugs Markets forYears 2006, 2009 & 2015

2.EUROPE

A. Market Analysis

Lung Cancer Therapeutics Market to WitnessRobust Growth

Product Approvals

Clinical Trials

B. Market Analytics

Table 6: European Recent Past, Current & FutureAnalysis for Non-Small Cell Lung Cancer Therapeuticsby Geographic Region - France, Germany, Italy, UKand Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through2015 (includes corresponding Graph/Chart)

Table 7: European 10-Year Perspective for Non-SmallCell Lung Cancer Therapeutics Market by Geographic Region - Percentage Breakdown of Annual Revenuesfor France, Germany, Italy, UK and Rest of EuropeMarkets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2a.FRANCE

A. Market Analysis

Overview of Lung Cancer Market

Key Player

B. Market Analytics

Table 8: French Recent Past, Current & Future Analysisfor Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million forYears 2005 through 2015 (includes corresponding Graph/Chart)

2b.GERMANY

A. Market Analysis

Lung Cancer Scenario

Chemotherapy Gains Preference

Strategic Corporate Developments

B. Market Analytics

Table 9: German Recent Past, Current & Future Analysisfor Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million forYears 2005 through 2015 (includes corresponding Graph/Chart)

2c.ITALY

A. Market Analysis

Incidence in Women on Rise

Treatment

B. Market Analytics

Table 10: Italian Recent Past, Current & Future Analysisfor Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million forYears 2005 through 2015 (includes corresponding Graph/Chart)

2d.THE UNITED KINGDOM

A. Market Analysis

British Women at Higher Risk

Fast Facts

Proposed Cancer Care Improvements Mulled byBritish Government

NICE Recommends Use of Erlotinib in NSCLCTreatment

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 11: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005through 2015 (includes corresponding Graph/Chart)

2e.REST OF EUROPE

A. Market Analysis

Outlook

Strategic Corporate Developments

Key Player

B. Market Analytics

Table 12: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$Million for Years 2005 through 2015 (includescorresponding Graph/Chart)

3.REST OF WORLD

A. Market Analysis

Australia

Fast Facts

Brazil

China

Overview of NSCLC Drug Market

India

Japan

Product Launches

Strategic Corporate Development

B. Market Analytics

Table 13: Rest of World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$Million for Years 2005 through 2015 (includescorresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 191 (including Divisions/Subsidiaries - 200)

Region/Country Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Rest of Europe

Asia-Pacific (Excluding Japan)

Abstract

This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs. The report provides separate comprehensive analytics for the US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2005 through 2015. The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co. Ltd., Telik, Inc., and Woomera Therapeutics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.